Oral KDS2010 , a Monoamine Oxidase‐B ( MAO ‐B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO‐B‐Mediated Inflammation
Journal of Neurochemistry · 2025
DOI: 10.1111/jnc.70302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurochemistry, 2025. Verfasst von Dong Ho Woo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Biopharmaceutical Research, Korea Institute of Toxicology, Daejeon, South Korea. Hauptthemen laut MEDLINE: Monoamine Oxidase Inhibitors, Spinocerebellar Ataxias, Astrocytes, Monoamine Oxidase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by balance and gait disturbance, muscle coordination deficits, and dysarthria as a primary symptom. SCA1 is caused by the expansion of CAG repeats in the ATXN1 gene, leading to a polyglutamine(polyQ) tract in the Ataxin‐1 protein. In this study, the effects of KDS2010, an inhibitor of monoamine oxidase‐B (MAO‐B), were evaluated in a transgenic mouse model of SCA1 (SCA1 154Q/2Q ) disease model using the rotarod, hindlimb, and open field tests. In both males and females, oral administration of KDS2010 significantly improved latency in the rotarod test and the hindlimb clasping phenotype without changing muscle weight. In the open field test, a notable improvement in moving distance was observed particularly in females. Treatment with KDS2010 slowed molecular layer atrophy and restored the reduced number of Purkinje cells in the cerebellum of SCA1 model mice, accompanied by decreased levels of glial fibrillary acidic protein (GFAP) and reduced expression of monoamine oxidase‐B (MAO‐B). These results indicate that KDS2010 ameliorated the behavioral pathology of SCA1 by attenuating GFAP upregulation and preventing Purkinje cell loss. Our findings demonstrate that KDS2010 improves SCA1‐related behavioral deficits by reducing GFAP expression, preserving Purkinje cell numbers, and decreasing cerebellar MAO‐B levels—molecular markers of SCA1, without affecting muscle size. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Global Biopharmaceutical Research, Korea Institute of Toxicology, Daejeon, South Korea.
- Human and Environmental Toxicology, University of Science and Technology, Daejeon, Republic of Korea.
- Center for the Rare Disease Therapeutic Technology, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, South Korea.
- Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
ORCID-Profile: Dong Ho Woo
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Woo, D. H., Jeon, J. H., Ryu, H. J., Lee, G. M., Lim, H. W., Park, K. D., Hoe, K. L., & Rhee, S. D. (2025). Oral KDS2010 , a Monoamine Oxidase‐B ( MAO ‐B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO‐B‐Mediated Inflammation. Journal of Neurochemistry. https://doi.org/10.1111/jnc.70302
Vancouver
Woo DH, Jeon JH, Ryu HJ, Lee GM, Lim HW, Park KD, et al. Oral KDS2010 , a Monoamine Oxidase‐B ( MAO ‐B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO‐B‐Mediated Inflammation. Journal of Neurochemistry. 2025. doi:10.1111/jnc.70302
BibTeX
@article{Woo2025,
author = {Woo, Dong Ho and Jeon, Ju-Hyun and Ryu, Hye-Jin and Lee, Gyeong Min and Lim, Hye-Won and Park, Ki Duk and Hoe, Kwang Lae and Rhee, Sang Dal},
title = {Oral KDS2010 , a Monoamine Oxidase‐B ( MAO ‐B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO‐B‐Mediated Inflammation},
journal = {Journal of Neurochemistry},
year = {2025},
doi = {10.1111/jnc.70302}
}
EUVIMED